TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06362005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone Acetonide 0.1% Oint
Description: RCT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tacrollimus Topical
Description: RCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium
Description: RCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium & Triamcinolone Acetonide 0.1% Oint
Description: RCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium& Tacrollimus topical
Description: RCT
Study: NCT04594187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: All patients must be planned for treatment with any immunotherapy agent after sentinel lymph node biopsy (e.g. pembrolizumab or nivolumab). For patients receiving radiation therapy initiation may be before, during or after radiation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: All patients must be planned for treatment with any immunotherapy agent after sentinel lymph node biopsy (e.g. pembrolizumab or nivolumab). For patients receiving radiation therapy initiation may be before, during or after radiation.
Study: NCT04854395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcain 5 mg/ml
Description: Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
Study: NCT04594187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04854395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcain 5 mg/ml
Description: Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcain 5 mg/ml
Description: Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
Study: NCT04594187

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo nodal radiation therapy
Study: NCT04638322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIFT Group
Description: An experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the HIFT method, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 min per session. Once the intervention is finished, you will undergo a final evaluation to see if there is a difference or not with the results obtained at the beginning.
Study: NCT05044884

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circuit training
Description: 1. Functional strength exercises Heel raise, toe raise, walking on toes, step ups in all directions ( forward, backward and sideways) (2 sets and 8 reps)~2. Stance exercises Tandem, narrow, one leg stance, and stand on uneven surfaces with open eyes (each exercise 30 seconds) Tandem, narrow, one leg stance, and stand on uneven surfaces with eyes closed (each exercise 15seconds).~3. Transition exercises Sit to stand from chair with arms (10 reps) and then without arms support (5 reps).~   Sit on floor and stand up with assistance and then without assistance.~4. Gait training Walking tandem, sideway and backward with arm support. Walking tandem, sideway and backward without arm support Walking tandem, sideway and backward over obstacles~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles
Study: NCT06105320

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LCHF
Description: A diet intervention with the following macronutrient targets:~Carbohydrates: 10-25 E%; Fat 50-70 E%; Protein: 20-25 E%; Alcohol 0-5 E%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LCHF
Description: A diet intervention with the following macronutrient targets:~Carbohydrates: 10-25 E%; Fat 50-70 E%; Protein: 20-25 E%; Alcohol 0-5 E%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HCLF
Description: A diet intervention with the following macronutrient targets:~Carbohydrates: 50-60 E%; Fat 25-30 E%; Protein: 15-20 E%; Alcohol 0-5 E%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HCLF
Description: A diet intervention with the following macronutrient targets:~Carbohydrates: 50-60 E%; Fat 25-30 E%; Protein: 15-20 E%; Alcohol 0-5 E%
Study: NCT05015920

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD211 Drug Product
Description: Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding βA-T87Q-Globin.
Study: NCT05778656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Risk Prevention with a Mediterranean Dietary Pattern Reduced in Saturated Fat
Description: Eight-week behavioral intervention consisting of a Mediterranean dietary pattern with elimination of red and processed meat
Study: NCT05980598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon TLR7/8 Agonist
Description: TLR7/8 agonist prodrug
Study: NCT06064812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FWD1802
Description: Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FWD1802
Description: Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FWD1802
Description: Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbocilib
Description: The palbociclib dose is the fixed approved dose: 125 mg intake daily, for consecutive 21 days then off for 7 days, which composes 28-day treatment cycle, which is consistent with the 28-day treatment cycle of FWD1802.~Every treatment cycle consists of 28 days.
Study: NCT05980598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon TLR7/8 Agonist
Description: TLR7/8 agonist prodrug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: A type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Description: Sustained systemic release of IL-2 β/γ with selective receptor binding that may stimulate the immune system to kill cancer cells
Study: NCT06633757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCT1100
Description: mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
Study: NCT05714566

Intervention type: DIAGNOSTIC_TEST
Intervention: Clostridioides difficile toxin detection
Description: Using Genexpert kit to detect the stool samples of IBD patients. If C. difficile toxin is positive, the patient is assigned to IBD+CDI group, or else assigned to IBD group. Every sample assigned to Health control group should have negative results for C.difficile toxin tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clostridioides difficile toxin detection
Description: Using Genexpert kit to detect the stool samples of IBD patients. If C. difficile toxin is positive, the patient is assigned to IBD+CDI group, or else assigned to IBD group. Every sample assigned to Health control group should have negative results for C.difficile toxin tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clostridioides difficile toxin detection
Description: Using Genexpert kit to detect the stool samples of IBD patients. If C. difficile toxin is positive, the patient is assigned to IBD+CDI group, or else assigned to IBD group. Every sample assigned to Health control group should have negative results for C.difficile toxin tests.
Study: NCT04808882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin, Low dose prophylactic anticoagulation
Description: Participants randomized to the LD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: LD-PA : 3500 IU/24h. Depending on the type of tinzaparin pre-filled syringe available in the participating center, the dose of 4000 IU/24h will be allowed in place of 3500 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: LD-PA: 4000 IU/24h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin, High dose prophylactic anticoagulation
Description: Participants randomized to the HD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: HD-PA : 7000 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: HD-PA: 4000 IU/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin,Therapeutic anticoagulation
Description: Participants randomized to the TA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: TA : 175 IU/kg/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: TA: 100 IU/kg/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data.
Study: NCT05192759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: The stimulations were performed by MagStim Rapid2.
Study: NCT05212064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow oxygen nasal cannula therapy
Description: Heated and humidified oxygen of 40L/minute through high-flow nasal cannula (HFNC) therapy machine.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: nasal cannula oxygen therapy
Description: Heated and humidified oxygen of 6L/minute through high-flow nasal cannula (HFNC) therapy machine.
Study: NCT06505564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AVATAR therapy
Description: In the initial phase of treatment, patients collaborate with therapists to visualize the source of their auditory hallucinations. Therapists adjust their voice to match the hallucinations, prompting patients to recall key statements for future sessions. Subsequent sessions involve dialogues with a computerized avatar. Using the altered voice, therapists interact in real-time through the avatar, engaging patients in role-playing. They alternate between the avatar and supportive therapist roles to empower patients with positive affirmations and discussions. Sessions last approximately 50 minutes, utilizing Oculus Rift VR headsets and noise-cancelling headphones to enhance immersion. HEKA VR software adjusts avatar proximity, and patients have the option to record dialogues for home use and sharing. Therapists receive bi-weekly supervision from HEKA VR-trained colleagues. Participants continue their regular medication prescribed by their psychiatrists alongside this experimental therapy
Study: NCT05618366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive oral venetoclax taken once per day. The dose will be between 200 and 800 mg daily, with the exact dose determined by the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat 800mg taken orally, twice daily.
Study: NCT05519202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1,Oxaliplatin, Penpulimab
Description: S-1 ( 40 mg/m2 bid po d1-14) and Penpulimab (200mg ivgtt d1) and Oxaliplatin ( 130 mg/m2 (d1)
Study: NCT06666829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidomain intervention
Description: treatment plan using combination of more than one technological or robotic devices, choosing from: Virtual Reality Rehabilitation System (VRSS), Khymeia TR; HomeKIT Khymeia; VRSS Khymeia EVO; Myro® Tyromotion; Diego Tyromotion; Tyrostation Tyromotion; Pablo® Tyromotion; Amadeo Tyromotion; Lexo® Tyromotion; Humaware MObile RoboT for upper Limb NeurOortho Rehabilitation (MOTORE); Humanware Upper Limb TRAcker(ULTRA+); Gloreha Sinfonia plus; C-Mill Motek; Gait Real Time Analysis Laboratory (GRAIL) Motek Medical; Nirvana BTS; Agilik; Armeo Spring pediatrico Hocoma; Lokomat ® Hocoma; Hand Tutor, Leg Tutor, Arm Tutor (MediTouch); Care Lab; Dessintey IVS3; Rehacom Hasomed; Hunova; GEO System (Kineo).~In this way, the child will be taken care of holistically, considering their needs from a motor, cognitive, and speech therapy perspective. The treatment plan will also include a conventional multi-level rehabilitation program.
Study: NCT05471245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magic Touch SCB by Concept Medical Inc.
Description: PCI with drug-coated balloon
Study: NCT06666829

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single domain intervention
Description: Treatment plan using only one of these technological or robotic device:~Virtual Reality Rehabilitation System (VRSS), Khymeia TR; HomeKIT Khymeia; VRSS Khymeia EVO; Myro® Tyromotion; Diego Tyromotion; Tyrostation Tyromotion; Pablo® Tyromotion; Amadeo Tyromotion; Lexo® Tyromotion; Humaware MObile RoboT for upper Limb NeurOortho Rehabilitation (MOTORE); Humanware Upper Limb TRAcker(ULTRA+); Gloreha Sinfonia plus; C-Mill Motek; Gait Real Time Analysis Laboratory (GRAIL) Motek Medical; Nirvana BTS; Agilik; Armeo Spring pediatrico Hocoma; Lokomat ® Hocoma; Hand Tutor, Leg Tutor, Arm Tutor (MediTouch); Care Lab; Dessintey IVS3; Rehacom Hasomed; Hunova; GEO System (Kineo).~Technological rehabilitation will focus on the main specific need for the child, it'll be chosen individually. The treatment plan will also include a conventional multi-level rehabilitation program.
Study: NCT05122195

Intervention type: OTHER
Intervention: Compression therapy
Description: Graduated elastic compression promote venous flow which is impaired by hormonal changes in the venous system during the gestational period and minimize the blocking effect of the gravid uterus.
Study: NCT06677359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Group
Description: Micronized creatine monohydrate supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Group
Description: Micronized creatine monohydrate supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Participants will recieved placebo supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Group
Description: Participants will recieved placebo supplementation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent Training
Description: Multicomponent physical exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent Training
Description: Multicomponent physical exercise intervention
Study: NCT06020261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Management Training
Description: developing parenting skills and competencies dealing with oppositional and irritable behaviors in the child.
Study: NCT05568862

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler ultrasound, Urodynamic assessment.
Description: The patients included in the study group were given 600 cc of water in the morning and the Doppler ultrasound was performed 30 minutes later

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler ultrasound, Urodynamic assessment.
Description: The patients included in the study group were given 600 cc of water in the morning and the Doppler ultrasound was performed 30 minutes later

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic assessment.
Description: A transurethral double lumen catheter was used to measure intravesical pressure in the urodynamic unit for the patients in the study group immediately after the use of the Doppler USG
Study: NCT04722003

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Group B Vaccine
Description: A combination vaccine consisting of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp), Outer Membrane Vesicles (OMV), aluminum hydroxide, sodium chloride, histidine, and sucrose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride, USP injection.
Study: NCT05904340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Transcutaneous Electrical Nerve Stimulation (TENS) uses machines to generate electric current, flows through the skin and conducts to the nerves, triggers a chain reaction of nerves through a new stimulus source, and achieves the effect of pain relief. Using different frequencies and intensities will Produce different effects and trigger different physiological mechanisms.
Study: NCT04241354

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte-poor platelet rich plasma
Description: Platelet rich plasma was prepared using PurePRP Supra Physiologic Protocol A preparation \[EmCyte Corp. Fort Myers FL\].

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte-poor platelet rich plasma
Description: Platelet rich plasma was prepared using PurePRP Supra Physiologic Protocol A preparation \[EmCyte Corp. Fort Myers FL\].
Study: NCT05341869

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Para-cervical block
Description: Block of inferior hypogastric plexus with local anesthetic

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Para-cervical block
Description: Block of inferior hypogastric plexus with local anesthetic
Study: NCT05800041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX221
Description: Drug: WTX221 WTX221 infusion once every 30 days for two doses in total Drug: CTX Co-administration of CTX and WTX221 at the initial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX221
Description: Drug: WTX221 WTX221 infusion once every 30 days for two doses in total Drug: CTX Co-administration of CTX and WTX221 at the initial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX221
Description: Drug: WTX221 WTX221 infusion once every 30 days for two doses in total Drug: CTX Co-administration of CTX and WTX221 at the initial infusion
Study: NCT06459063

Intervention type: DRUG
Group type: OTHER
Intervention: Allocetra - Safety run-in phase
Description: Intra-articular injection of Allocetra performed once on Day 1 of the study at different doses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra-articular injection of placebo solution containing all excipients except for the Allocetra cells.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allocetra - Randomization phase
Description: Intra-articular injection of selected dose of Allocetra based on the safety run-in, performed on Day 1 of the study.
Study: NCT05012241

Intervention type: DIAGNOSTIC_TEST
Intervention: Nine Hole Peg Test
Description: At first, each patient will be asked to fill in the questionnaire. Then he/she will be tested by the Nine Hole Peg Test according to the new Czech version of extended manual for this test. Audio recording of verbal instructions will be used.
Study: NCT04765774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ekspressive touch
Description: Patients will be divided into three groups. The expressive touch group will touch the patient's hand.
Study: NCT04894812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental technique
Description: 1. st month: postural maintenance; exercises with weight on forearms and hands, in sitting, crawling, semi-kneeling and standing positions with support from therapist.~2. nd month: balance and corrective reactions; using CP ball and tilt board.~3. rd month: ambulation training; appropriate to motor development level (crawling, creeping, walking in a semi-kneeling position and walking between parallel bars).